Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02167035 · ClinicalTrials.gov registry record · Phase 4
Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)
A Phase 4 study of Glaucoma and Ocular Hypertension, sponsored by Cornerstone Health Care, PA.
- Completed
- Registry status
- Phase 4
- Development phase
- 43
- Enrollment target
- 1
- Study location
NCT02167035: Completed Phase 4 study of Glaucoma and Ocular Hypertension, sponsored by Cornerstone Health Care, PA.
NCT02167035 is a Phase 4 study of Glaucoma and Ocular Hypertension that has completed, run by Cornerstone Health Care, PA. The registered enrollment target is 43 participants, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (95% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02167035, a Phase 4 study of Glaucoma and Ocular Hypertension, has completed, sponsored by Cornerstone Health Care, PA.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 43 participants
- Enrollment target
- 1
- Study location
Study Summary
To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hypertension. The purpose of this clinical trial would be to assess which treatment, if either, is superior in lowering intraocular pressure (IOP). A secondary objective is to assess the tolerability of each drug.
Primary Outcome
The Intraocular Pressure will be assessed on study subjects. IOP (Intraocular Pressure) will be measured using a Goldmann applanation tonometer. Both eyes will be tested, with the right eye preceding the left eye. The operator will initially set the dial at 10 mmHg, then look through the slit lamp and adjust the dial to take the reading, and then record the results. The procedure will be repeated on the same eye twice consecutively. If the measurements are within 2mmHg or less of each other, the
Conditions Studied
Interventions
- DRUG Combigan Two Times Daily (BID)
- DRUG Simbrinza Three Times Daily (TID)
Study Locations (1)
North Carolina
- Cornerstone Health Care - High Point
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 43 participants |
| Start Date | 2014-08 |
| Est. Completion | 2018-03 |
| Phase | Phase 4 |
What the finished NCT02167035 record still lists
NCT02167035 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 43 participants, a relatively small participant target, below the 910-participant average among 92 other Glaucoma trials with a reported enrollment target (95% lower).
The record links to 2 conditions, with Glaucoma appearing as the primary indexed condition, and to 2 interventions - of which Combigan Two Times Daily (BID) is the first listed.
NCT02167035 reports a single indexed study location in North Carolina.
Frequently Asked Questions
What is clinical trial NCT02167035 about?
NCT02167035 is a clinical study titled "Comparison of Combigan Two Times Daily (BID) Versus Simbrinza Three Times Daily (TID)". To compare Combigan Two Times Daily (BID) vs Simbrinza Three Times Daily (TID) in subjects currently being treated with Latanoprost for Open-Angle Glaucoma or Ocular Hypertension. Both of these drugs are currently FDA approved as combination therapy for patients with Open-Angle Glaucoma or Ocular Hy...
What is the current status of trial NCT02167035?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 43 participants. The study started on 2014-08. Estimated completion is 2018-03.
What conditions does trial NCT02167035 study?
This clinical trial studies the following conditions: Glaucoma, Ocular Hypertension.
What interventions are being tested in trial NCT02167035?
The interventions under investigation include: Combigan Two Times Daily (BID) (DRUG), Simbrinza Three Times Daily (TID) (DRUG).
Who is sponsoring clinical trial NCT02167035?
This trial is sponsored by Cornerstone Health Care, PA, which has 2 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT02167035 being conducted?
This trial has 1 study location across North Carolina. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Glaucoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT02167035's enrollment target sits among peer trials
43 73rd of 92 higher than 20 of 92 other Glaucoma trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Glaucoma trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Retinal Blood Flow and Autoregulation
RECRUITING · Phase 4
-
Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanoprost 0.005% to Treat Glaucoma
RECRUITING · Phase 4
-
Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use
RECRUITING · Phase 4
-
Examining The Efficacy, Safety And Improved Tolerability Of Travoprost BAK Free Ophthalmic Solution (Travatan-Z) Compared To Prior Prostaglandin Therapy
COMPLETED · Phase 4
-
Efficacy of Bimatoprost 0.03% in Patients Who Are Low-Responders to Latanoprost
COMPLETED · Phase 4
-
Aqueous Humor Dynamic Components That Determine Intraocular Pressure Variance
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03726359 · 43 participants · Phase 1
Phase I Study of Fractionated Stereotactic Radiation Therapy
- NCT03850418 · 43 participants · Phase 2
Azacitidine and Chimerism in MDS or AML Patients After Allogeneic Stem Cell Transplant
- NCT04144023 · 43 participants · Phase 1
A Vaccine (H2NVAC) Before Surgery for the Treatment of HER2-Expressing Ductal Carcinoma In Situ
- NCT04176718 · 43 participants · Phase 2
Daratumumab, Carfilzomib, Pomalidomide, Dexamethasone In MM
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia